April 7, 2017
Takeda Pharmaceutical has obtained exclusive worldwide rights to FIN-524, a synthetic microbiome therapy for inflammatory bowel disease (IBD) being developed by US biotech Finch Therapeutics, the two companies said on April 5. FIN-524 is a live biotherapeutic product in pre-clinical...read more